Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience.

CONCLUSIONS: Everolimus, and to a lesser extent sirolimus, are increasingly being used to treat TSC infants and very young children for multiple TSC-associated clinical indications. While AEs were common, most were not severe and did not prevent continued treatment in the majority of this younger population. PMID: 30005812 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30005812?dopt=Abstract

Source: European Journal of Paediatric Neurology - July 4, 2018 Category: Neurology Authors: Krueger DA, Capal JK, Curatolo P, Devinsky O, Ess K, Tzadok M, Koenig MK, Narayanan V, Ramos F, Jozwiak S, de Vries P, Jansen AC, Wong M, Mowat D, Lawson J, Bruns S, Franz DN, TSCure Research Group Tags: Eur J Paediatr Neurol Source Type: research